Emerging infections: surveillance, epidemiology and pathogenesis

项目摘要 在过去的25年里，由于气候变化，蜱传疾病的发病率显著增加， 人类和蜱虫的人口统计学变化以及病媒控制不足。包括经济 和社会成本，据估计，蜱传疾病的成本在50至100亿美元之间，每年。 美国疾病控制和预防中心目前确认了18种不同的蜱传病原体， 美国的随着每年新的病毒和病原体的发现，这一数字可能会上升。 这些病原体之一是波旁病毒（BRBV），这是一种新出现的蜱传RNA病毒，可以感染并引起 人类的疾病。没有抗病毒疗法或疫苗可用，突出了开发 针对这些威胁生命的疾病的对策。该应用程序的主要目标是开发 针对BRBV的mRNA疫苗，在BRBV小鼠模型中评价其体内功效，并确定 作用机制。第二个目标是测试不同的病毒抗原和mRNA疫苗设计， 多价mRNA疫苗。成功完成拟议的研究将提供初步数据， R01申请旨在开发一种通用疫苗，可提供针对蜱虫和蜱传播的保护 病原体在美国。

PROJECT SUMMARY The incidence of tick-borne diseases has increased significantly over the past 25 years due to climate change, shifting population demographics of both humans and ticks, and inadequate vector control. Including economic and societal costs, it is estimated that tick-borne diseases costs between 50 and 100 billion dollars each year. The Center for Disease Control and Prevention currently recognizes 18 different tick-transmitted pathogens in the United States. This number is likely to rise as novel viruses and pathogens are being discovered each year. One of these pathogens is Bourbon virus (BRBV), an emerging tick-borne RNA virus that can infect and cause disease in humans. No antiviral therapies or vaccines are available, highlighting the need to develop countermeasures against these life-threatening diseases. The primary objective of this application is to develop an mRNA vaccine against BRBV, evaluate its efficacy in vivo in a mouse model of BRBV and determine the mechanism of action. A secondary goal is to test different viral antigens and mRNA vaccine designs to improve multivalent mRNA vaccines. Successful completion of the proposed studies will provide the preliminary data for a R01 application aimed at developing a universal vaccine that confers protection against tick and tick-borne pathogens in the United States.